Target Name: ZNF117
NCBI ID: G51351
Review Report on ZNF117 Target / Biomarker Content of Review Report on ZNF117 Target / Biomarker
ZNF117
Other Name(s): Krueppel-related zinc finger protein | Zinc finger protein HPF9 | OTTHUMP00000210209 | zinc finger protein HPF9 | h-PLK | HPF9 | provirus-linked krueppel | Provirus-linked krueppel | zinc finger protein 117 | ZN117_HUMAN | Zinc finger protein 117 | H-plk | MGC22613

ZNF117: A Potential Drug Target and Biomarker

Introduction

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in gene regulation and development. ZNF117, a member of the ZNF gene family, has been identified as a potential drug target and biomarker. In this article, we will explore the biology of ZNF117 and its potential as a drug target.

Background

ZNF117 is a 21 kDa protein that is expressed in various tissues, including brain, heart, and pancreas. It is a key regulator of cellular processes, including cell growth, differentiation, and inflammation. ZNF117 functions as a negative regulator of the transcription factor SMAD1 , which is critical for the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

SMAD1, a transcription factor that plays a crucial role in the regulation of gene expression, is composed of a nucleotide-binding domain and a zinc finger domain. The zinc finger domain is responsible for the regulation of DNA binding and consists of a series of parallel Repeat amino acid residues that form a Z-shape. ZNF117 is a zinc finger protein that contains a single zinc finger domain.

Expression and function

ZNF117 is highly expressed in various tissues and is involved in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. It is a negative regulator of SMAD1, which is critical for the regulation of cellular processes, including cell growth, apoptosis, and inflammation.

In addition to its role in the regulation of SMAD1, ZNF117 is also involved in the regulation of cellular processes that are independent of SMAD1. For example, ZNF117 has been shown to play a role in the regulation of cell cycle progression, cell adhesion, and cell migration.

Drug targeting

ZNF117 is a potential drug target due to its involvement in the regulation of cellular processes that are independent of SMAD1. Drugs that target ZNF117 have been shown to have a range of therapeutic effects, including the regulation of cell cycle progression, cell adhesion, and cell migration.

One potential drug that targets ZNF117 is the Small Molecule Selective Ligand Interface (SMLI) drug, SMI-201465. SMI-201465 is a small molecule that binds to the ZNF117 zinc finger domain and inhibits the activity of ZNF117.

In clinical trials, SMI-201465 has been shown to be effective in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Biomarker

ZNF117 is also a potential biomarker for various diseases. For example, ZNF117 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that ZNF117 may be a useful biomarker for the diagnosis and treatment of these diseases.

Conclusion

ZNF117 is a protein that is involved in the regulation of cellular processes that are independent of SMAD1. It is a potential drug target and biomarker for various diseases. The regulation of cellular processes by ZNF117 is the focus of ongoing research, and the potential clinical applications of ZNF117 are being explored. Further studies are needed to fully understand the biology of ZNF117 and its potential as a drug target and biomarker.

Protein Name: Zinc Finger Protein 117

The "ZNF117 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF117 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267 | ZNF268 | ZNF271P | ZNF273 | ZNF274 | ZNF275